Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects
Completed · Phase 1
Conditions studied: Healthy Volunteers
In brief
Primary Objective: Determine blood concentrations of two formulations of REGN2222 Secondary Objective: Assess safety and tolerability of REGN2222
Key facts
- Study ID
- NCT02828397
- Run by
- Regeneron Pharmaceuticals
- People needed
- 28
- Starts
- 2016-04-01
- Expected to finish
- 2016-09-01
- Last updated by the study team
- 2016-11-04
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — Daytona Beach, Florida, United States
- Study site — Evansville, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.